To the full analysis
Embla Medical hf. stock: growth
EMBLA.COEmbla Medical hf. reported $963.59M in revenue for fiscal 2025, up 12.7% on the prior year, up 8.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.3%
per year from 2006 to 2025, per share 6.7%
Earnings (Annual rate)
17%
per year from 2006 to 2025, per share 16.3%
Free cash flow (Annual rate)
18.4%
per year from 2006 to 2025, per share 17.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 8.9% | 7.1% | 7.3% |
| Revenue per share | 8.6% | 7.6% | 6.7% |
| Earnings | 69.3% | 5.4% | 17.0% |
| Earnings per share | 68.6% | 5.2% | 16.3% |
| Free cash flow | 11.8% | 11.1% | 18.4% |
| Free cash flow per share | 11.5% | 11.5% | 17.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $252.13M | $4.36M | $4.83M |
| 2007 | $335.61M | $7.58M | $28.13M |
| 2008 | $350.02M | $28.49M | $45.08M |
| 2009 | $330.58M | $22.76M | $69.16M |
| 2010 | $358.54M | $35.36M | $30.69M |
| 2011 | $401.33M | $36.63M | $32.3M |
| 2012 | $399.44M | $38.45M | $43.25M |
| 2013 | $436.27M | $40.48M | $49.1M |
| 2014 | $509.36M | $59.45M | $68.36M |
| 2015 | $483.03M | $51.24M | $41.66M |
| 2016 | $520.75M | $51.03M | $41.73M |
| 2017 | $568.62M | $57.65M | $54.73M |
| 2018 | $612.88M | $79.75M | $38.58M |
| 2019 | $686.26M | $66.04M | $63.43M |
| 2020 | $629.5M | $6.21M | $68.22M |
| 2021 | $718.67M | $63.99M | $73.84M |
| 2022 | $718.65M | $42.51M | $34.83M |
| 2023 | $799.07M | $58.39M | $52.05M |
| 2024 | $854.89M | $68.28M | $0 |
| 2025 | $963.59M | $86.47M | $118.94M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Nov 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.